KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Assets: 2013-2024

Historic Current Assets for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $635.3 million.

  • Xenon Pharmaceuticals' Current Assets fell 27.21% to $480.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $480.1 million, marking a year-over-year decrease of 27.21%. This contributed to the annual value of $635.3 million for FY2024, which is 1.50% down from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' Current Assets is $635.3 million, which was down 1.50% from $645.0 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Current Assets peaked at $645.0 million during FY2023, and registered a low of $181.8 million during FY2020.
  • Over the past 3 years, Xenon Pharmaceuticals' median Current Assets value was $635.3 million (recorded in 2024), while the average stood at $626.8 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Current Assets surged by 207.52% in 2021 and then declined by 1.50% in 2024.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Current Assets stood at $181.8 million in 2020, then skyrocketed by 207.52% to $559.0 million in 2021, then rose by 7.38% to $600.3 million in 2022, then climbed by 7.44% to $645.0 million in 2023, then fell by 1.50% to $635.3 million in 2024.